Development of anti-Bw6 reactivity in patients receiving r-GCSF: a preliminary report

Publications

Share / Export Citation / Email / Print / Text size:

Immunohematology

American National Red Cross

Subject: Medical Laboratory Technology

GET ALERTS SUBSCRIBE

ISSN: 0894-203X
eISSN: 1930-3955

DESCRIPTION

0
Reader(s)
0
Visit(s)
0
Comment(s)
0
Share(s)

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue / page

Archive
Volume 37 (2021)
Volume 36 (2020)
Volume 35 (2019)
Volume 34 (2018)
Volume 33 (2017)
Volume 32 (2016)
Volume 31 (2015)
Volume 30 (2014)
Volume 29 (2013)
Volume 28 (2012)
Volume 27 (2011)
Volume 26 (2010)
Volume 25 (2009)
Volume 24 (2008)
Volume 23 (2007)
Volume 22 (2006)
Volume 21 (2005)
Volume 20 (2004)
Volume 19 (2003)
Volume 18 (2002)
Volume 17 (2001)
Volume 16 (2000)
Volume 15 (1999)
Volume 14 (1998)
Volume 13 (1997)
Volume 12 (1996)
Volume 11 (1995)
Volume 10 (1994)
Volume 9 (1993)
Volume 8 (1992)
Volume 7 (1991)
Volume 6 (1990)
Volume 5 (1989)
Volume 4 (1988)
Volume 3 (1987)
Related articles

VOLUME 17 , ISSUE 3 (September 2001) > List of articles

Development of anti-Bw6 reactivity in patients receiving r-GCSF: a preliminary report

Miriam Fogg Leach / James P. AuBuchon

Keywords : r-GCSF, marrow/progenitor cell transplant, anti-Bw6

Citation Information : Immunohematology. Volume 17, Issue 3, Pages 63-69, DOI: https://doi.org/10.21307/immunohematology-2019-549

License : (Transfer of Copyright)

Published Online: 14-October-2020

ARTICLE

ABSTRACT

Recombinant granulocyte colony-stimulating factor (r-GCSF) is used in autologous bone marrow/peripheral blood progenitor cell transplantation (ABMT/PBPC) to shorten the period of neutropenia. As these patients require platelet transfusions, their sera may be monitored for the presence of platelet/human leukocyte antigen (HLA) antibodies. Sera of some patients on r-GCSF (16 μg/kg/day) became difficult to evaluate in vitro for the presence of HLA and platelet antibodies because of apparently anomalous reactions in solid phase red cell adherence (SPRCA) assays. SPRCA tests were positive only when platelets were adhered to the polystyrene plates in the presence of glucose; when other simple sugars were used, the patients’ sera failed to react. HLA Bw6-positive platelets were more likely than HLA Bw6-negative platelets to be reactive (þ < .001). The transfusion of HLA Bw6-positive platelets to patients displaying this in vitro reactivity (positive patients) resulted in a 50 percent lower corrected count increment (CCI) than those given to patients without it (negative patients; þ= <.001). When all transfusions were considered, the CCI for those of the positive patients was decreased 73 percent when compared to the control patients = .0005). The presence of the antibody also was associated with a twofold increase in the number of platelet transfusions given (þ = .0005). ABMT/PBPC patients receiving r-GCSF may develop unexpected reactions on SPRCA antibody screens and poor responses to transfusion of Bw-6-positive platelets.

You don't have 'Full Text' access of this article.

Purchase Article Subscribe Journal Share